Delolimogene mupadenorepvec - Lokon Pharma
Alternative Names: LOAd 703Latest Information Update: 20 Jan 2025
Price :
$50 *
At a glance
- Originator Lokon Pharma
- Developer Lokon Pharma; Uppsala University
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action 4-1BB ligand expression stimulants; CD40 ligand expression stimulants; Cell death stimulants; Dendritic cell stimulants; Immunologic cytotoxicity; Macrophage stimulants; Natural killer cell stimulants; T-cell receptor gene stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cancer; Malignant melanoma
- Research Breast cancer; Sarcoma
- No development reported B-cell lymphoma; Multiple myeloma
Most Recent Events
- 13 Sep 2024 Adverse events and efficacy data from a phase-I/II trial in Malignant melanoma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024), ,
- 13 Sep 2024 Adverse events and efficacy data from a phase-I/II trial in Cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024), ,
- 28 Sep 2023 No recent reports of development identified for preclinical development in B-cell lymphoma in Sweden (Intratumoural, Injection)